Prognostic significance of BACH2 expression in diffuse large B-cell lymhomna: A study of the Osaka Lymphoma Study Group

被引:37
作者
Sakane-Ishikawa, E
Nakatsuka, S
Tomita, Y
Fujita, S
Nakamichi, I
Takakuwa, T
Sugiyama, H
Fukuhara, S
Hino, M
Kanamaru, A
Soma, T
Tsukaguchi, M
Igarashi, K
Kanakura, Y
Aozasa, K
机构
[1] Osaka Univ, Grad Sch Med, Dept Pathol C3, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan
[3] Osaka Univ, Grad Sch Med, Dept Funct Diagnost Sci, Suita, Osaka 5650871, Japan
[4] Kansai Med Univ, Dept Internal Med 1, Osaka, Japan
[5] Osaka City Univ, Dept Clin Hematol & Clin Diagnost, Osaka 558, Japan
[6] Kinki Univ, Sch Med, Dept Hematol, Osaka 589, Japan
[7] Osaka Miami Med Ctr, Dept Clin Lab, Osaka, Japan
[8] Sakai Municipal Hosp, Dept Hematol, Osaka, Japan
[9] Hiroshima Univ, Grad Sch Biomed Sci, Dept Biomed Chem, Hiroshima, Japan
关键词
D O I
10.1200/JCO.2005.02.1626
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose BACH2, a B-cell-specific transcription repressor, is abundantly expressed in lymphocytes of B-cell lineage as well as B-cell lymphoma cell lines. BACH2 possesses an inhibitory effect on proliferation of Raji cell lines derived from Burkitt's lymphoma. In this study, the prognostic significance of BACH2 expression was examined in diffuse large B-cell lymphoma (DLBCL). Patients and Methods BACH2 expression was immunohistochemically examined on the paraffin-embedded sections obtained by biopsy from 108 patients (62 males and 46 females; age range, 23 to 85 years) with DLBCL. Staining intensity in the cytoplasm of the tumor cells was categorized as equal to or stronger (level 1) or weaker (level 2) than that in the endothelial cells in the same specimens. Results Level 1 and 2 expression of BACH2 was found in 32.4% and 67.6% of patients, respectively. Patients with level 1 expression showed significantly better disease-free and overall survival rate than those with level 2 expression (both P < .05). Multivariate analysis revealed BACH2 expression level together with performance status, elevated serum level of lactate dehydrogenase, and treatment response to be independent factors for prognosis of the patients. Conclusion BACH2 expression level is a useful marker to predict disease-free and overall survival of patients with DLBCL.
引用
收藏
页码:8012 / 8017
页数:6
相关论文
共 25 条
[1]  
Ajiki W, 2000, JPN J CLIN ONCOL, V30, P318
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]  
[Anonymous], J R STAT SOC
[4]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[5]   COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA [J].
FISHER, RI ;
GAYNOR, ER ;
DAHLBERG, S ;
OKEN, MM ;
GROGAN, TM ;
MIZE, EM ;
GLICK, JH ;
COLTMAN, CA ;
MILLER, TP .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (14) :1002-1006
[6]   COMPARISON OF A 2ND-GENERATION COMBINATION CHEMOTHERAPEUTIC REGIMEN (M-BACOD) WITH A STANDARD REGIMEN (CHOP) FOR ADVANCED DIFFUSE NON-HODGKINS-LYMPHOMA [J].
GORDON, LI ;
HARRINGTON, D ;
ANDERSEN, J ;
COLGAN, J ;
GLICK, J ;
NEIMAN, R ;
MANN, R ;
RESNICK, GD ;
BARCOS, M ;
GOTTLIEB, A ;
OCONNELL, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (19) :1342-1349
[7]   Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J].
Hans, CP ;
Weisenburger, DD ;
Greiner, TC ;
Gascoyne, RD ;
Delabie, J ;
Ott, G ;
Müller-Hermelink, HK ;
Campo, E ;
Braziel, RM ;
Jaffe, ES ;
Pan, ZG ;
Farinha, P ;
Smith, LM ;
Falini, B ;
Banham, AH ;
Rosenwald, A ;
Staudt, LM ;
Connors, JM ;
Armitage, JO ;
Chan, WC .
BLOOD, 2004, 103 (01) :275-282
[8]   World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997 [J].
Harris, NL ;
Jaffe, ES ;
Diebold, J ;
Flandrin, G ;
Muller-Hermelink, HK ;
Vardiman, J ;
Lister, TA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3835-3849
[9]   Real time quantitative PCR [J].
Heid, CA ;
Stevens, J ;
Livak, KJ ;
Williams, PM .
GENOME RESEARCH, 1996, 6 (10) :986-994
[10]   DETECTION OF SPECIFIC POLYMERASE CHAIN-REACTION PRODUCT BY UTILIZING THE 5'-]3' EXONUCLEASE ACTIVITY OF THERMUS-AQUATICUS DNA-POLYMERASE [J].
HOLLAND, PM ;
ABRAMSON, RD ;
WATSON, R ;
GELFAND, DH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (16) :7276-7280